Apheresis to remove interfering substances
OwnerHenry J. Smithinventor
Life of this patent
Estimating the term…
Abstract
Cancer patients have circulating tumor cell components in their blood. When a therapeutic biologic or biosimilar is administered intravenously into the patient it can bind to these tumor cell components causing adverse side-effects. This invention teaches a targeted apheresis method of removing these interfering tumor cell components by binding them out using an immobilized binding agent contained within an apheresis device, and returning the treated blood back to the patient. Reducing the level of circulating tumor cell components before administering a biologic or biosimilar will increase its safety and efficacy in treating the tumor.
Claims7
A targeted apheresis method of removing circulating tumor cell components present in blood;
- wherein the removal of said tumor cell components would reduce the adverse side-effects commonly encountered when a therapeutic biologic or biosimilar is administered to the patient;
- and wherein said treatment will increase the bioavailability of the biologic or biosimilar to treat the tumor.
Dependencies are inferred from the claim text.